Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights

Published on February 6, 2026
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company in the retina space, has reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. The company reported total net revenue of $13.3 million for the fourth quarter of 2025, a 22.4 percent decrease compared with $17.1 million in the same period of 2024. For the full year, total net revenue was $52.0 million, down 18.5 percent from $63.7 million in 2024, the company announcement said.
Continue reading on website
Other news

Clinique Joins Forces With Acuvue on Visionary Collaboration to Advance Eye Education in Beauty and Vision

February 6, 2026
NEW YORK—Clinique, a leading dermatologist guided skincare to makeup brand, has announced a visionary collaboration in the U.S. with Acuvue, a leading contact lens brand from Johnson & Johnson Vision, to advance eye education in beauty and vision by informing consumers that they can wear contacts and eye makeup confidently. The collaboration highlights Clinique’s ability to create high-performance

SECO International Reveals 2026 Awards of Excellence Winners

February 6, 2026
ATLANTA—SECO International has announced the recipients of the 2026 SECO Awards of Excellence, recognizing extraordinary individuals and organizations whose dedication strengthens patient care, advances professional education, and elevates optometry across the South and beyond. The awards honor leaders in optometry, opticianry, paraoptometric, and professional service. SECO 2026, one of the larges